Recursion Pharmaceuticals, Inc. financial statements, including revenue, expenses, profit, and loss
The total revenue of RXRX for the last quarter is 10.89 M USD, and it's 3.40% higher compared to the previous quarter. The net income of Q4 23 is -93.00 M USD.